ASCO GU 2021 Prostate Cancer - Results from #40

Viewing 41-60 of 83 articles

ASCO GU 2021: Beyond the Basics: Harnessing the Immune System to Fight Prostate Cancer

ASCO GU 2021: Back to Basics in Personalization: Returning to PTEN

ASCO GU 2021: Association of Co-Occurring Gene Alterations and Clinical Activity of Rucaparib in Patients with BRCA1 or BRCA2 Mutated (BRCA+) Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2021: PI3K/AKT Pathway Biomarkers Analysis from the Phase III IPATential150 Trial of Ipatasertib plus Abiraterone in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2021: Genomic Analysis of Circulating Tumor DNA in Patients with Advanced Prostate Cancer to Identify Targetable BRCA Alterations and AR Resistance Mechanisms

ASCO GU 2021: PSMA-Targeted Imaging With 18F-DCFPyL-PET in Patients With Biochemically Recurrent Prostate Cancer

ASCO GU 2021: Androgen Deprivation Therapy and Risk of SARS-CoV-2 Infection in Men with Prostate Cancer: A University of California Health System Registry Study

ASCO GU 2021: Prevalence of Microsatellite Instability and Monitoring Response to Immune Checkpoint Inhibition Utilizing Liquid Biopsy Among African American Men with Advanced Prostate Cancer

ASCO GU 2021: Best of the Journals – Prostate Cancer: Medical Oncology

ASCO GU 2021: Use of Genomics to Guide Treatment Decisions in Post-Prostatectomy Patients

ASCO GU 2021: Prospective Randomized Trial of Gene Expression Classifier Utility Following Radical Prostatectomy (G-MINOR)

ASCO GU 2021: Randomized Phase II Trial of Radium-223 plus Enzalutamide Versus Enzalutamide Alone in mCRPC: Final Efficacy and Safety Results

ASCO GU 2021: Redefining High-Risk Prostate Cancer: Beyond Clinical Parameters

ASCO GU 2021: Exploratory Gene-By-Gene Analysis Of Olaparib In Patients With Metastatic Castration-Resistant Prostate Cancer: PROfound

ASCO GU 2021: Prospective Randomized Trial of Gene Expression Classifier Utility Following Radical Prostatectomy (G-MINOR)

ASCO GU 2021: Genomic Landscape of Advanced Prostate Cancer In Racial Minority Populations: Real-World Experience In A Safety-Net Hospital Oncology Clinic

ASCO GU 2021: Final Analysis Results from TITAN: A Phase III Study of Apalutamide Versus Placebo In Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving ADT

ASCO GU 2021: Discussion: Molecular Correlates of Response to Apalutamide in nmCRPC and Final Results from ACIS, Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC

ASCO GU 2021: KEYNOTE-365 Cohort B: Pembrolizumab Plus Docetaxel And Prednisone In Abiraterone Or Enzalutamide-Pretreated Patients with mCRPC: New Data After An Additional Year Of Follow-Up

ASCO GU 2021: PI3K/AKT Pathway Biomarkers Analysis From The Phase III IPATential150 Trial Of Ipatasertib Plus Abiraterone In Metastatic Castration-Resistant Prostate Cancer

1
2
3
4
5